BioNTech SE
BNTX · XNASCIK 1776985fmd_1X0DHMG96XV8RQBF51HFKZBSXAManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2017 to Dec 31, 2025, 9 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 62 | 128 | 109 | 482 | 18,977 | 17,311 | 3,819 | 2,751 | 2,870 |
| Cost of revenue | 9 | 14 | 17 | 59 | 2,912 | 2,995 | 600 | 541 | 642 |
| Gross profit | 52 | 114 | 91 | 423 | 16,065 | 14,316 | 3,219 | 2,210 | 2,228 |
| Research and development | 85 | 143 | 226 | 645 | 949 | 1,537 | 1,783 | 2,254 | 2,105 |
| Selling, general and administrative | 30 | 29 | 48 | 109 | 327 | 541 | 558 | 599 | 624 |
| Operating income | (61) | (54) | (182) | (82) | 15,284 | 12,643 | 690 | (1,314) | (1,405) |
| Interest expense | 26 | 0 | 2 | 65 | 305 | 19 | 24 | 27 | 70 |
| Income before taxes | (86) | (48) | (179) | (146) | 15,046 | 12,954 | 1,186 | (678) | (1,051) |
| Income tax expense | 0 | 1 | (0) | (161) | 4,754 | 3,520 | 256 | (12) | 85 |
| Net income from continuing operations | (86) | (48) | (179) | 15 | 10,293 | 9,434 | 930 | (665) | (1,136) |
| Net income | (86) | (48) | (179) | 15 | 10,293 | 9,434 | 930 | (665) | (1,136) |